Posts Tagged ‘buzz stocks’

BASI boosts, S steady, DBLE loses fuel

Monday, February 7th, 2011

Bioanalystical Systems Inc. (Nasdaq: BASI) grew in price 25 per cent Monday to $2.60, on volume of 111,964 shares, twice and a half its daily average, after reporting quarterly profit of $310,000, compared to a loss of $1.5 million in the prior-year quarter.

Sprint Nextel Corporation (Nasdaq: S) traded in 41.6 million shares, catching up on a daily average of 49.8 million. Share prices edged up 0.3 percent to $4.42, on word S was getting set to offer a dual-screen Android smartphone.

Double Eagle Petroleum Company (Nasdaq: DBLE) went south 13.7 percent Monday to $9.10. Volume was 1.2 million shares, towering over a daily average of 81,466. DBLE explores for, develops, and sells natural gas and crude oil, with natural gas constituting more than 95% of its production and reserves.

GKK gallops, CSCO clicks, CPE swoons

Monday, February 7th, 2011

Gramercy Capital Corp. (NYSE: GKK) vaulted 13.3 per cent to $4.68, on volume of 1.3 million shares, or better than twice its daily average. GKK is an integrated commercial real estate finance and property investment company.

Cisco Systems Inc. (Nasdaq: CSCO) traded in 31 million shares, tracking down a daily average of 73.6 million. Share prices nosed up 0.7 percent to $22.19

Callon Petroleum Company (NYSE: CPE) stumbled 8.8 percent Monday to $8.38. Volume was 1.4 million shares, compared to a daily average of 454,170. Monday, CPE announced it intends to offer nine million of its common shares.

NCAP headed north, TTIN solid, HPMFF goes home

Monday, February 7th, 2011

Northsight Capital Inc. (OTCBB: NCAP) went skyward Monday 121.9 percent in price to 60 cents. Volume for the stock was 50,600 shares, compared to a daily average of 7,863. Safe Communications, Inc. (Pink Sheets: SGTB) announced today that the company has signed a nonbinding agreement in principle with Northsight, under which NCAP would acquire the company’s newly formed corporate security division, NCAP Security Systems, Inc.

Transfer Technology International Corp (OTCBB: TTIN) dealt in 51.3 million shares Monday, compared to a daily average of 379,800. Prices gained 28 percent of traction to 96-100ths of a cent, only days after one of its subsidiaries announced its sale to a major drug store chain.

Homeland Precious Metals Corp. (OTCBB: HPMFF) fell with a thud Monday, draining off 90 percent in price to two cents. Volume for the stock was 26,618 shares, compared to a daily average of 2,239. The British Columbia-based HPMFF is engaged in the acquisition and exploration of natural resource properties.

REFR jumps, F steps on gas, TRGL trails

Monday, February 7th, 2011

Research Frontiers Inc. (Nasdaq: REFR) vaulted 35.62 per cent to $9.90, on volume of 613,204 or nearly 10 times its daily average. REFR has an investor conference call planned for Wednesday.

Ford Motor Company (NYSE: F) traded in 72.7 million shares, pursuing a daily average of 95 million. Share prices added 3.4 percent to $16.26. F says it is seeing “strong demand” for the new Focus in Europe and is expecting a “bumper sales month” in March when the vehicle is available across the region.

Toreador Resources Corporation (Nasdaq: TRGL) staggered 12.4 percent Monday to $13.16. Volume was 894,779 shares, better than twice its daily average.

LZR merges, MSFT moving, CRME skips a beat

Monday, February 7th, 2011

Emergent Group Inc. (AMEX: LZR) shares sprang up 38.8 per cent to $8.41, on volume of 284,325 or more than 11 times its daily average. Monday, it was announced that LZR was to be acquired by Universal Hospital Services for $8.46 a share.

Microsoft Inc. (Nasdaq: MSFT) traded in 25.3 million shares, pursuing a daily average of 58.4 million. Share prices added 1.6 percent to $28.22, amid general momentum in the tech world.

Cardiome Pharma Corporation (Nasdaq: CRME) lost 11.4 percent Monday to $6.06. Volume was 561,971 shares, nearly twice its normal daily average. Vancouver-based CRME is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system.